Please login to the form below

Not currently logged in
Email:
Password:

cediranib

This page shows the latest cediranib news and features for those working in and with pharma, biotech and healthcare.

AZ withdraws EU filing for ovarian cancer drug cediranib

AZ withdraws EU filing for ovarian cancer drug cediranib

While its role as a monotherapy is ended, cediranib remains an important component of AZ's combination therapy strategy in ovarian cancer. ... This decision does not affect the ongoing primary development programme testing cediranib as a combination

Latest news

  • ASCO: AZ’s ovarian cancer combination aces trial ASCO: AZ’s ovarian cancer combination aces trial

    Olaparib/cediranib combo demonstrates progression-free survival of 17.7 months. A combination therapy based on two AstraZeneca (AZ) compounds - olaparib and cediranib - has nearly doubled progression-free survival (PFS) compared ... Combining olaparib

  • Glioblastomas - a personalised future? Glioblastomas - a personalised future?

    Many agents have been unsuccessful. One of these, the pan-VEGF inhibitor cediranib, was discontinued at phase 3 due to disappointing results from pivotal studies.

  • Extending the arsenal

    It is also only one of a handful of therapies — along with aflibercept (Regeneron Pharmaceuticals), brivanib alaninate (Bristol-Myers Squibb) and cediranib (AstraZeneca) — in late-stage clinical trials for this type

  • AZ's Recentin trial disappoints

    AstraZeneca's colorectal cancer drug, Recentin (cediranib), has failed to match Roche's Avastin (bevacizumab) in a phase II/III comparison study. ... AstraZeneca (AZ) has announced that its colorectal cancer drug, Recentin (cediranib), has failed to

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics